Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Deffered Revenue (2016 - 2018)

VYNE Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $6.3 million for Q1 2018.

  • For Q1 2018, Non-Current Deffered Revenue changed N/A year-over-year to $6.3 million; the TTM value through Mar 2018 reached $6.3 million, changed N/A, while the annual FY2017 figure was $6.7 million, 21.05% down from the prior year.
  • Non-Current Deffered Revenue reached $6.3 million in Q1 2018 per VYNE's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $8.5 million in Q4 2016 to a low of $6.3 million in Q1 2018.
  • Average Non-Current Deffered Revenue over 3 years is $7.2 million, with a median of $6.7 million recorded in 2017.
  • The largest YoY upside for Non-Current Deffered Revenue was 21.05% in 2017 against a maximum downside of 21.05% in 2017.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $8.5 million in 2016, then fell by 21.05% to $6.7 million in 2017, then decreased by 6.67% to $6.3 million in 2018.
  • Per Business Quant, the three most recent readings for VYNE's Non-Current Deffered Revenue are $6.3 million (Q1 2018), $6.7 million (Q4 2017), and $8.5 million (Q4 2016).